查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
微生物组治疗市场规模和预测、全球和地区份额、趋势和成长机会分析（按类型、应用、最终用户和地理位置）
市场调查报告书
商品编码
1389658

微生物组治疗市场规模和预测、全球和地区份额、趋势和成长机会分析（按类型、应用、最终用户和地理位置）

Microbiome Therapeutics Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis By Type, Application, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 160 Pages | 订单完成后即时交付

价格

微生物组治疗市场预计将从2022年的3.7592亿美元成长到2030年的8.1338亿美元；预计2022年至2030年CAGR为10.1%。

人体微生物组包括人体内部和周围发现的所有微生物及其相关代谢物/产物。技术进步使得研究人类肠道微生物组在维持健康和疾病方面的多效作用成为可能。由于微生物在人类健康中具有广泛的潜力，因此它们具有用作疾病管理疗法的巨大潜力。微生物组疗法有望治疗任何严重类型的疾病，并透过克服各种环境中的人际变异性和稳定性等关键问题，成为实现个人化治疗目标的潜在来源。粪便微生物移植（FMT）或依赖外源性微生物施用的益生菌等策略可用于治疗与菌丛失调相关的疾病。

肠道微生物群在维持人类健康方面的潜力推动微生物组治疗市场的成长

微生物组疗法旨在透过使用噬菌体、细菌素、抗生素、天然或合成细菌，或减法或调节治疗来改变肠道微生物组。透过提供个人化、协调、可靠和持久的治疗，该策略可以克服传统疗法的限制。全球治疗市场已展现出其巨大的经济潜力。研究表明，使用微生物组疗法治疗发炎性肠道疾病、肥胖甚至精神健康障碍等疾病具有良好的效果。正在进行的研究也正在探索以微生物组为基础的干预措施在癌症治疗、糖尿病管理和心血管健康领域的潜力。此外，胃肠道疾病的发生率随着年龄的增长而增加，胃肠道联盟2021年2月的资料估计，近2,000万美国人患有慢性消化系统疾病，每年有超过6,200万美国人被诊断患有胃肠道疾病。国际胃肠道疾病基金会（IFFGD）发布的统计数据显示，GERD盛行率在北美为18%至28%，在南美为23%，在欧洲为9-26%。因此，在未来几年，胃肠道疾病发生频率的增加将推动市场扩张。

透过了解微生物组与疾病发展之间的复杂关係，科学家正在开发针对问题根源的个人化治疗方法，而不仅仅是控制症状。随着知识的扩展和技术的进步，微生物组疗法有可能成为现代医学的基石，为改善受一系列疾病影响的个人的健康结果带来希望。

人们越来越认识到微生物组在人类健康和疾病中的重要性，这鼓励了严格的研究和开发工作，以进一步了解人类微生物组并开发微生物组疗法。它帮助开发了潜在的疗法并确定了障碍。技术和研究工具的进步也促进了研发的成长。新一代定序和宏基因组分析可以对微生物组进行更全面、更详细的研究。这些工具使研究人员能够识别特定的微生物种类及其功能，并追踪微生物组随时间的变化。 FDA 等监管机构也支持微生物组治疗领域的研发工作。 FDA 制定了 FMT 指南，并有兴趣透过监管途径推进该领域的发展，以确保安全性和有效性。监管机构的这种支持为公司开发和测试基于微生物组的疗法提供了一个框架，使投资者对这些疗法的潜在成功充满信心。总体而言，对微生物组疗法的兴趣和资金的增加正在推动更多的研究和开发工作。这将有助于更好地了解人类微生物组，并开发出可以调节微生物组以改善人类健康的标靶疗法。

微生物组治疗市场根据类型、应用、最终用户和地理位置进行划分。微生物组治疗市场根据类型、应用和最终用户进行划分。根据类型，微生物组治疗市场分为治疗方法和手术方法。根据应用，微生物组治疗市场分为代谢紊乱和肥胖、艰难梭菌感染和发炎性肠道疾病。就最终用户而言，微生物组治疗市场分为医院和诊所、门诊手术中心和家庭护理。

根据地理位置，市场分为北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲。北美在微生物组治疗市场中占有最大的市场份额。由于艰难梭菌病例的增加、技术的进步以及人们对肠道微生物群重要性的认识不断提高，北美占据了重要的市场份额。人们越来越了解人类微生物组在维持健康和预防疾病方面的重要性，这促使美国研究人员探索基于微生物组的干预措施，作为治疗各种疾病的一种有前景的方法。此外，该国在微生物组治疗市场的主导地位主要归因于其发达的研究基础设施，有利于创新疗法的开发此外，肥胖和炎症性肠道疾病等慢性病患病率的上升创造了对创新疗法的需求治疗，刺激微生物组疗法的发展。基因定序和生物资讯学的技术进步使得微生物组的研究和改变成为可能，从而促进基于微生物组的个人化干预措施的发展。个人化医疗的趋势与客製化微生物组疗法非常吻合。学术界、工业界和政府组织之间的合作也正在推动研究和开发工作，加速将科学发现转化为商业产品。由于监管机构认识到微生物组疗法的潜力并为其开发和批准提供指导，该领域的监管支持和投资进一步促进了市场成长。

对研究和创新的重视使人们对肠道微生物群对健康的影响有了深入的了解，为基于微生物组的治疗奠定了坚实的基础。加拿大生物技术和製药的支持性监管环境鼓励公司投资于以微生物组为重点的研究和开发。此外，创投和政府资助的增加也为这项研究注入了资金。 2020 年 1 月，加拿大政府及其合作伙伴投资 1,800 万美元用于重要的微生物组研究。

加拿大人对肠道健康和微生物组在整体健康中的重要性的认识不断提高，刺激了消费者对基于微生物组的产品的需求。此外，加拿大微生物组计划 (CMI) 等措施的广泛实施使得在加拿大与合作伙伴和利益相关者的合作变得更加容易。这使得将研究工作集中在微生物疗法的开发上成为可能。学术机构、生技公司和医疗保健组织之间的合作和伙伴关係加速了研究和开发工作。此外，加拿大公司正在开拓国际市场，扩大微生物组疗法的范围。所有这些因素结合在一起表明微生物组疗法在加拿大的前景光明。

ClinicalTrails.com、疾病管制与预防中心 (CDC) 以及食品药物管理局 (FDA) 是在准备微生物组治疗市场报告时参考的几个关键的主要和次要来源。

目录

第 1 章：简介

  • Insight Partners 研究报告指南
  • 市场区隔

第 2 章：执行摘要

  • 微生物组治疗市场（按地理位置）

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：微生物组治疗市场格局

  • 概述
  • PEST分析
    • 全球PEST分析

第 5 章：微生物组治疗市场 - 主要产业动态

  • 市场驱动因素：
    • 肠道微生物群在维持人类健康的潜力
    • 资金流入改善微生物组发现管道
  • 市场限制
    • 开发和生产成本高
  • 市场机会
    • 加强研发以更了解人类微生物组
  • 未来的趋势
    • 人类微生物组治疗的技术进步
  • 影响分析：

第 6 章：微生物组治疗市场 - 全球市场分析

  • 微生物组治疗市场收入，2020 - 2030

第 7 章：全球微生物组治疗市场 - 2030 年收入与预测 - 按类型

  • 概述
  • 2022 年和 2030 年按类型分類的微生物组治疗市场收入份额 (%)
  • 程式
  • 疗法

第 8 章：全球微生物组治疗市场 - 2030 年收入和预测 -按应用

  • 概述
  • 2022 年及 2030 年微生物组治疗市场收入份额（按应用划分）（%）
  • 代谢紊乱与肥胖
  • C. 艰难梭菌感染 (CDI)
  • 发炎性肠道疾病
  • 其他的

第 9 章：全球微生物组治疗市场 - 收入和 2030 年预测 - 按最终用户

  • 概述
  • 微生物组治疗市场收入份额（按最终用户），2022 年和 2030 年 (%)
  • 医院和诊所
  • 门诊手术中心
  • 居家护理
  • 其他的

第 10 章：微生物组治疗市场 - 地理分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：微生物组治疗市场 - 产业格局

  • 概述
  • 微生物组治疗市场的成长策略
  • 无机成长策略
    • 概述
  • 有机成长策略
    • 概述

第 12 章：公司简介

  • Enterome
  • Finch Therapeutics Group Inc
  • Caelus Health
  • Ferring Pharmaceuticals
  • Pendulum Therapeutics INC
  • AOBiome
  • Seres Therapeutics
  • Vedanta Biosciences
  • COST-BRY Pty Ltd (BiomeBank)
  • YSOPIA Bioscience

第 13 章：附录

  • 关于我们
  • 专业术语
Product Code: TIPRE00027698

The microbiome therapeutics market is expected to grow from US$ 375.92 million in 2022 to US$ 813.38 million by 2030; it is anticipated to record a CAGR of 10.1% from 2022 to 2030.

The human microbiome includes all the microorganisms and their related metabolites/products identified in and around the human body. Technological advancement has enabled the examination of the pleiotropic effects of the human gut microbiome in maintaining health and diseases. With the extensive potential of microbes in human health, they hold enormous potential to be used as therapeutics for disease management. Microbiome therapy holds great promise to treat any severe type of disease condition and acts as the potential source to achieve the objective of personalized therapy by overcoming key issues like interpersonal variability and stability in every type of environment. Strategies such as fecal microbiota transplantation (FMT) or probiotics that rely on the administration of exogenous microbes could be used to manage dysbiosis-related disorders.

Potential of Gut Microbiota in Maintaining Human Health drives the growth the Microbiome Therapeutics Market

Microbiome therapeutics are aimed at modifying the gut microbiome by using bacteriophages, bacteriocins, antibiotics, native or synthetic bacteria, or subtractive or modulatory treatment. By offering individualized, harmonized, dependable, and long-lasting therapy, this strategy can overcome the limitations of traditional therapies. The global therapeutics market has demonstrated its enormous economic potential. Studies have shown promising results in using microbiome therapeutics for conditions such as inflammatory bowel disease, obesity, and even mental health disorders. Ongoing research is also exploring the potential of microbiome-based interventions in areas of cancer treatment, diabetes management, and cardiovascular health. Further, the incidence of gastrointestinal illnesses increases with age, and the GI Alliance data from February 2021 estimates that almost 20 million Americans have chronic digestive diseases, and over 62 million Americans receive a diagnosis of gastrointestinal diseases each year. The International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) released statistics showing that GERD prevalence ranges from 18% to 28% in North America, 23% in South America, and 9-26% in Europe. Therefore, in the upcoming years, the increasing frequency of gastrointestinal disorders will fuel the market expansion.

By understanding the intricate relationship between microbiome and disease development, scientists are developing personalized treatments that target the root cause of the problem rather than merely managing symptoms. As knowledge expands and technologies advance, microbiome therapeutics have the potential to become a cornerstone of modern medicine, offering hope for improved health outcomes for individuals affected by a range of diseases.

The growing recognition of the microbiome's importance in human health and disease has encouraged rigorous research and development efforts to further understand the human microbiome and develop microbiome therapeutics. It has helped develop potential therapeutics and identify hindrances. Advancements in technology and research tools have also contributed to growing R&D. Next-generation sequencing and metagenomic analysis have allowed for a more comprehensive and detailed study of the microbiome. These tools enable researchers to identify specific microbial species and their functions, as well as track changes in the microbiome over time. Regulatory agencies, such as the FDA, are also supporting R&D efforts in the field of microbiome therapeutics. The FDA has established guidelines for FMT and has developed interest in advancing the field through regulatory pathways to ensure safety and efficacy. This support from regulatory agencies provides a framework for companies to develop and test microbiome-based therapies, giving investors confidence in the potential success of these treatments. Overall, the increased interest and funding in microbiome therapeutics are driving more research and development efforts. This will lead to a better understanding of the human microbiome and the development of targeted therapies that can modulate the microbiome to improve human health.

The microbiome therapeutics market is divided on the basis of type, application, end user, and geography. The microbiome therapeutics market is divided on the basis of type, application, and end user. Based on type, the microbiome therapeutics market is segmented into therapeutics and procedures. By application, the microbiome therapeutics market is segmented into metabolic disorders and obesity, C. difficile infection, and inflammatory bowel diseases. In terms of end users, the microbiome therapeutics market is classified as hospitals and clinics, ambulatory surgery centers, and home care.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the microbiome therapeutics market. North America accounts for a significant market share owing to the growing incidences of C. difficile cases, technological advances, and growing awareness about the importance of gut microbiota. The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treat various conditions. Additionally, the dominance of this country in the microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

An emphasis on research and innovation has yielded a significant understanding of the impact of gut microbiota on health, providing a solid foundation for microbiome-based therapeutics. A supportive regulatory environment for biotechnology and pharmaceuticals in Canada has encouraged companies to invest in microbiome-focused research and development. Additionally, increased venture capital investments and government funding have infused capital into this research. In January 2020, the Government of Canada, along with its partners, invested US$ 18 million in crucial microbiome research.

The rising awareness among Canadians about the importance of gut health and microbiome in overall well-being has spurred consumer demand for microbiome-based products. Moreover, the widespread implementation of initiatives such as the Canadian Microbiome Initiative (CMI) makes working with partners and stakeholders easier in Canada. This makes it possible to concentrate research efforts on the development of microbiome therapies. Collaborations and partnerships between academic institutions, biotechnology firms, and healthcare organizations have accelerated research and development efforts. Moreover, Canadian companies are exploring international markets, expanding the reach of microbiome therapeutics. All these factors combined indicate a promising trajectory for microbiome therapeutics in Canada.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA), are a few key primary and secondary sources referred to while preparing the report on the microbiome therapeutics market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the microbiome therapeutics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the microbiome therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the microbiome therapeutics market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Microbiome Therapeutics Market, by Geography

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Microbiome Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Global PEST Analysis

5. Microbiome Therapeutics Market - Key Industry Dynamics

  • 5.1 Market Drivers:
    • 5.1.1 Potential of Gut Microbiota in Maintaining Human Health
    • 5.1.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Development and Production
  • 5.3 Market Opportunities
    • 5.3.1 Increasing R&D to Gain Better Understanding of Human Microbiome
  • 5.4 Future Trends
    • 5.4.1 Technological Advancement in Human Microbiome Therapeutics
  • 5.5 Impact Analysis:

6. Microbiome Therapeutics Market - Global Market Analysis

  • 6.1 Microbiome Therapeutics Market Revenue (US$ Mn), 2020 - 2030

7. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by Type

  • 7.1 Overview
  • 7.2 Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
  • 7.3 Procedure
    • 7.3.1 Overview
    • 7.3.2 Procedure: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Therapeutics
    • 7.4.1 Overview
    • 7.4.2 Therapeutics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.1 Global: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)

8. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
  • 8.3 Metabolic Disorder and Obesity
    • 8.3.1 Overview
    • 8.3.2 Metabolic Disorder and Obesity: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 C. Difficile Infection (CDI)
    • 8.4.1 Overview
    • 8.4.2 C. Difficile Infection (CDI): Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Inflammatory Bowel Disease
    • 8.5.1 Overview
    • 8.5.2 Inflammatory Bowel Disease: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Microbiome Therapeutics Market Revenue Share, by End User, 2022 & 2030 (%)
  • 9.3 Hospitals and Clinics
    • 9.3.1 Overview
    • 9.3.2 Hospitals and Clinics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Ambulatory Surgical Centers
    • 9.4.1 Overview
    • 9.4.2 Ambulatory Surgical Centers: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Homecare
    • 9.5.1 Overview
    • 9.5.2 Homecare: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Microbiome Therapeutics Market - Geographical Analysis

  • 10.1 North America Microbiome Therapeutics Market, Revenue and Forecast To 2030
    • 10.1.1 Overview
    • 10.1.2 North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.1.3 North America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.1.3.1 North America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.1.4 North America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.1.5 North America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.1.6 North America Microbiome Therapeutics Market, by Country
      • 10.1.6.1 US
        • 10.1.6.1.1 Overview
        • 10.1.6.1.2 US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.1.3 US: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.1.6.1.3.1 US: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.1.6.1.4 US: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.6.1.5 US: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.1.6.2 Canada
        • 10.1.6.2.1 Overview
        • 10.1.6.2.2 Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.2.3 Canada: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.1.6.2.3.1 Canada: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.1.6.2.4 Canada: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.6.2.5 Canada: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.1.6.3 Mexico
        • 10.1.6.3.1 Overview
        • 10.1.6.3.2 Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.3.3 Mexico: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.1.6.3.3.1 Mexico: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.1.6.3.4 Mexico: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.6.3.5 Mexico: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.2 Europe Microbiome Therapeutics Market, Revenue and Forecast to 2030
    • 10.2.1 Overview
    • 10.2.2 Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.2.3 Europe: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.2.3.1 Europe: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.2.4 Europe: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.2.5 Europe: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.2.6 Europe Microbiome Therapeutics Market, by Country
      • 10.2.6.1 UK
        • 10.2.6.1.1 Overview
        • 10.2.6.1.2 UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.1.3 UK: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.1.3.1 UK: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.1.4 UK: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.1.5 UK: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.2 Germany
        • 10.2.6.2.1 Overview
        • 10.2.6.2.2 Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.2.3 Germany: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.2.3.1 Germany: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.2.4 Germany: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.2.5 Germany: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.3 France
        • 10.2.6.3.1 Overview
        • 10.2.6.3.2 France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.3.3 France: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.3.3.1 France: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.3.4 France: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.3.5 France: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.4 Italy
        • 10.2.6.4.1 Overview
        • 10.2.6.4.2 Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.4.3 Italy: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.4.3.1 Italy: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.4.4 Italy: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.4.5 Italy: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.5 Spain
        • 10.2.6.5.1 Overview
        • 10.2.6.5.2 Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.5.3 Spain: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.5.3.1 Spain: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.5.4 Spain: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.5.5 Spain: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.7 Rest of Europe
        • 10.2.6.7.1 Overview
        • 10.2.6.7.2 Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.7.3 Rest of Europe: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.7.3.1 Rest of Europe: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.7.4 Rest of Europe: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.7.5 Rest of Europe: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.3 Asia Pacific Microbiome Therapeutics Market, Revenue and Forecast to 2030
    • 10.3.1 Overview
    • 10.3.2 Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.3.3 Asia Pacific: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.3.3.1 Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.3.4 Asia Pacific: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.3.5 Asia Pacific: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.3.6 Asia Pacific Microbiome Therapeutics Market, by Country
      • 10.3.6.1 China
        • 10.3.6.1.1 Overview
        • 10.3.6.1.2 China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.1.3 China: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.1.3.1 China: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.1.4 China: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.1.5 China: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.2 Japan
        • 10.3.6.2.1 Overview
        • 10.3.6.2.2 Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.2.3 Japan: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.2.3.1 Japan: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.2.4 Japan: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.2.5 Japan: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.3 India
        • 10.3.6.3.1 Overview
        • 10.3.6.3.2 India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.3.3 India: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.3.3.1 India: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.3.4 India: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.3.5 India: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.4 Australia
        • 10.3.6.4.1 Overview
        • 10.3.6.4.2 Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.4.3 Australia: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.4.3.1 Australia: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.4.4 Australia: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.4.5 Australia: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.5 South Korea
        • 10.3.6.5.1 Overview
        • 10.3.6.5.2 South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.5.3 South Korea: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.5.3.1 South Korea: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.5.4 South Korea: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.5.5 South Korea: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.7 Rest of Asia Pacific
        • 10.3.6.7.1 Overview
        • 10.3.6.7.2 Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.7.3 Rest of Asia Pacific: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.7.3.1 Rest of Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.7.4 Rest of Asia Pacific: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.7.5 Rest of Asia Pacific: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.4 Middle East & Africa Microbiome Therapeutics Market, Revenue and Forecast to 2030
    • 10.4.1 Overview
    • 10.4.2 Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.4.3 Middle East & Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.4.3.1 Middle East & Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.4.4 Middle East & Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.4.5 Middle East & Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.1 Middle East & Africa Microbiome Therapeutics Market, by Country
      • 10.4.5.2 Saudi Arabia
        • 10.4.5.2.1 Overview
        • 10.4.5.2.2 Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.2.3 Saudi Arabia: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.4.5.2.3.1 Saudi Arabia: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.4.5.2.4 Saudi Arabia: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.4.5.2.5 Saudi Arabia: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.3 South Africa
        • 10.4.5.3.1 Overview
        • 10.4.5.3.2 South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.3.3 South Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.4.5.3.3.1 South Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.4.5.3.4 South Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.4.5.3.5 South Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.4 UAE
        • 10.4.5.4.1 Overview
        • 10.4.5.4.2 UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.4.3 UAE: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.4.5.4.3.1 UAE: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.4.5.4.4 UAE: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.4.5.4.5 UAE: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.5 Rest of Middle East Africa
        • 10.4.5.5.1 Overview
        • 10.4.5.5.2 Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.5.3 Rest of Middle East Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.4.5.5.3.1 Rest of Middle East Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.4.5.5.4 Rest of Middle East Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.4.5.5.5 Rest of Middle East Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.5 South & Central America Microbiome Therapeutics Market, Revenue and Forecast to 2030
    • 10.5.1 Overview
    • 10.5.2 South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.5.3 South & Central America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.5.3.1 South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.5.4 South & Central America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.5.5 South & Central America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.5.6 South & Central America Microbiome Therapeutics Market, by Country
      • 10.5.6.1 Brazil
        • 10.5.6.1.1 Overview
        • 10.5.6.1.2 Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.1.3 Brazil: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.5.6.1.3.1 Brazil: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.5.6.1.4 Brazil: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.5.6.1.5 Brazil: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.5.6.2 Argentina
        • 10.5.6.2.1 Overview
        • 10.5.6.2.2 Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.2.3 Argentina: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.5.6.2.3.1 Argentina: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.5.6.2.4 Argentina: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.5.6.2.5 Argentina: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.5.6.3 Rest of South & Central America
        • 10.5.6.3.1 Overview
        • 10.5.6.3.2 Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.3.3 Rest of South & Central America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.5.6.3.3.1 Rest of South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.5.6.3.4 Rest of South & Central America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.5.6.3.5 Rest of South & Central America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)

11. Microbiome Therapeutics Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Microbiome Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Enterome
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Finch Therapeutics Group Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Caelus Health
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Ferring Pharmaceuticals
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Pendulum Therapeutics INC
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 AOBiome
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Seres Therapeutics
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Vedanta Biosciences
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 COST-BRY Pty Ltd (BiomeBank)
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 YSOPIA Bioscience
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Microbiome Therapeutics Market Segmentation
  • Table 2. Global Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America Microbiome Therapeutics Market, by Type- Revenue and Forecast to 2030 (US$ Million)
  • Table 4. North America Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 5. North America Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. North America Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. US Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. US Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 9. US Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 10. US Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Canada Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Canada Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Canada Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Mexico Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Mexico Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Mexico Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Mexico Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Europe Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Europe Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 21. Europe Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. Europe Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. UK Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. UK Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 25. UK Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 26. UK Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 27. Germany Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. Germany Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Germany Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Germany Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 31. France Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. France Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 33. France Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 34. France Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 35. Italy Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 36. Italy Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 37. Italy Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 38. Italy Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 39. Spain Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 40. Spain Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 41. Spain Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 42. Spain Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 43. Rest of Europe Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 48. Rest of Europe Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 49. Rest of Europe Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 50. Rest of Europe Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 51. Asia Pacific Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 52. Asia Pacific Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 53. Asia Pacific Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 54. Asia Pacific Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 55. China Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 56. China Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 57. China Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 58. China Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 59. Japan Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 60. Japan Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 61. Japan Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 62. Japan Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 63. India Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 64. India Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 65. India Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 66. India Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 67. Australia Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 68. Australia Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 69. Australia Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 70. Australia Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 71. South Korea Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 72. South Korea Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 73. South Korea Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 74. South Korea Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 75. Rest of Asia Pacific Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 108. Rest of Asia Pacific Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 109. Rest of Asia Pacific Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 110. Rest of Asia Pacific Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 111. Middle East & Africa Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 112. Middle East & Africa Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 113. Middle East & Africa Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 114. Middle East & Africa Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 115. Saudi Arabia Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 116. Saudi Arabia Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 117. Saudi Arabia Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 118. Saudi Arabia Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 119. South Africa Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 120. South Africa Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 121. South Africa Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 122. South Africa Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 123. UAE Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 124. UAE Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 125. UAE Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 126. UAE Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 127. Rest of Middle East Africa Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 128. Rest of Middle East Africa Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 129. Rest of Middle East Africa Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 130. Rest of Middle East Africa Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 131. South & Central America Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 132. South & Central America Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 133. South & Central America Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 134. South & Central America Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 135. Brazil Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 136. Brazil Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 137. Brazil Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 138. Brazil Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 139. Argentina Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 140. Argentina Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 141. Argentina Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 142. Argentina Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 143. Rest of South & Central America Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 144. Rest of South & Central America Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 145. Rest of South & Central America Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 146. Rest of South & Central America Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 147. Recent Inorganic Growth Strategies in the Microbiome Therapeutics Market
  • Table 148. Recent Organic Growth Strategies in Microbiome Therapeutics Market
  • Table 149. Glossary of Terms, Microbiome Therapeutics Market

List Of Figures

  • Figure 1. Microbiome Therapeutics Market Segmentation, By Geography
  • Figure 2. Global - PEST Analysis
  • Figure 3. Microbiome Therapeutics Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Microbiome Therapeutics Market Revenue (US$ Mn), 2020 - 2030
  • Figure 6. Microbiome Therapeutics Market Revenue, Geography (US$ Mn), 2022 - 2030
  • Figure 7. Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
  • Figure 8. Procedure: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Therapeutics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
  • Figure 11. Metabolic Disorder and Obesity: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. C. Difficile Infection (CDI): Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Inflammatory Bowel Disease: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Otehrs: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Microbiome Therapeutics Market Revenue Share, End User, 2022 & 2030 (%)
  • Figure 16. Hospitals and Clinics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Ambulatory Surgical Centers: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Homecare: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. North America: Microbiome Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 21. North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. North America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 23. US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 25. Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Europe Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 27. Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. Europe Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 29. UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 30. Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 32. Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 33. Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 34. Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 36. Asia Pacific Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 37. Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 38. Asia Pacific Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 39. China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 40. Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 41. India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 42. Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 43. South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 44. Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 53. Middle East & Africa Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 54. Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 55. Middle East & Africa Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 56. Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 57. South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 58. UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 59. Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 60. South & Central America Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 61. South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 62. South & Central America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 63. Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 64. Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 65. Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 66. Growth Strategies in Microbiome Therapeutics Market